For the quarter ending 2026-03-31, RGNX made $6,393K in revenue. -$90,234K in net income. Net profit margin of -1411.45%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 6,393 | 30,337 | 29,733 | 21,359 |
| Cost of license and royalty revenues | 11,074 | 5,928 | 5,725 | 5,209 |
| Research and development | 57,339 | 59,611 | 56,101 | 59,500 |
| General and administrative | 21,306 | 22,380 | 20,253 | 19,883 |
| Other operating expenses | -36 | -54 | -65 | -45 |
| Total operating expenses | 89,755 | 87,973 | 82,144 | 84,637 |
| Income (loss) from operations | -83,362 | -57,636 | -52,411 | -63,278 |
| Interest income from licensing | 16 | 18 | 19 | 21 |
| Investment income | 2,003 | 2,745 | 3,620 | 3,379 |
| Interest expense | 8,708 | 12,276 | 13,169 | 10,993 |
| Total other income (expense) | -6,689 | -9,513 | -9,530 | -7,593 |
| Net income (loss) | -90,051 | -67,149 | -61,941 | -70,871 |
| Unrealized gain on available-for-sale securities, net | -183 | -35 | 98 | 12 |
| Total other comprehensive gain | -183 | -35 | 98 | 12 |
| Comprehensive income (loss) | -90,234 | -67,184 | -61,843 | -70,859 |
| Basic EPS | -1.72 | -1.298 | -1.2 | -1.38 |
| Diluted EPS | -1.72 | -1.3 | -1.2 | -1.38 |
| Basic Average Shares | 52,428,000 | 51,758,000 | 51,689,000 | 51,483,000 |
| Diluted Average Shares | 52,428,000 | 51,686,000 | 51,689,000 | 51,483,000 |
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)